Key Laboratory of Magnetic Materials and Devices & Key Laboratory of Additive Manufacturing Materials of Zhejiang Province & Division of Functional Materials and Nanodevices, Ningbo Institute of Materials Technology and Engineering, Chinese Academy of Sciences, Ningbo 315201, PR China; Nano Science and Technology Institute, University of Science and Technology of China, Suzhou 215123, PR China
Auto-generated profile, based on publicly available information
Yuchen Tian
Key Laboratory of Magnetic Materials and Devices & Key Laboratory of Additive Manufacturing Materials of Zhejiang Province & Division of Functional Materials and Nanodevices, Ningbo Institute of Materials Technology and Engineering, Chinese Academy of Sciences, Ningbo 315201, PR China; Nano Science and Technology Institute, University of Science and Technology of China, Suzhou 215123, PR China
Neuropeptide Y (NPY) was first identified from porcine brain in 1982, and plays its biological functions in humans through NPY receptors (Y1, Y2, Y4 and Y5). NPY receptors are known to mediate various physiological functions and involve in a majority of human diseases, such as obesity, hypertension, epilepsy and metabolic disorders. Recently, NPY receptors have been found to be overexpressed in many cancers, so they emerged as promising target in cancer diagnosis and therapy. This review focuses on the latest research about NPY and NPY receptors, and summarizes the current knowledge on NPY receptors expression in cancers, selective ligands for NPY receptors and their application in cancer imaging and therapy.
Three dimensional plasmonic assemblies of gold nanoparticles (AuNPs) (gold 3D-PAs) have been recently developed for photothermal therapy, Raman imaging, photoacoustic imaging or X-ray computed tomography imaging because they can generate an enhanced electromagnetic field between the gaps of neighboring AuNPs and significantly improve the localized surface plasmon resonance (LSPR) effect in the near-infrared (NIR) region. However, the sizes of most reported gold 3D-PAs are too large (>300 nm) for in vivo applications as cancer theranostic agents because a size of about 200 nm is often considered to be the upper limit for successful drug delivery based on the enhanced permeation and retention (EPR) effect. Herein, we propose a novel strategy to fabricate the gold 3D-PAs with an overall size of sub-200 nm, whose self-assembly process was verified by TEM, DLS and UV-vis spectroscopy. The cell experiments demonstrate that our gold 3D-PAs allow combined chemotherapy and photothermal therapy. The histopathology assessments indicate that the toxicity of our gold 3D-PAs to normal tissues (side effect) is negligible. The animal experiments indicate that our gold 3D-PAs have a weak chemotherapeutic efficacy without NIR laser irradiation at a low DOX dosage, but shows an excellent therapeutic effect with NIR laser irradiation at the same DOX dosage due to the synergy of chemo-photothermal therapy.
6 October 2016 in The Journal of Physical Chemistry C